Share Price, page-12198

Our market cap is roughly 1.72b AUD which includes 213m cash, and 1/3 of a PRV (our share worth between 50m - 100m AUD). We are also incredibly likely to receive a $50M USD sales milestone either this quarter, or next, worth another $75m AUD~ or so. Our existing operating costs are covered by license income from a single geography from Daybue which is estimated between (132-138m including the sales milestone). We have incredibly strong results for 3 NNZ-2591 drugs in separate indications that points to platform drug potential, and we're working cooperatively with the FDA to launch the first ever Pivotal trial for Phelan McDermid syndrome which we can comfortably afford ourselves without raising, or partnering, despite partner interest being there. We just had a meeting to confirm that despite being the first Phase 3 for this condition and first Phase 3 for NNZ-2591 we won't need as strict safety guidelines, and the trial length is shorter than what was required for Trof despite the multiple Phase 2s (including placebo/blinded in Phase 2 which Trof 2256 had.

I understand sentiment is a factor, but we have been hit -35% in 6 months for what amounts to a single digit change in short term earnings and everything else that has occurred has added immense value to the company.